Header Logo

Connection

JOSEPH JANKOVIC to Parkinson Disease

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Parkinson Disease.
JOSEPH JANKOVIC
Connection Strength
39.195
Parkinson Disease
  1. Response to the letter "Reassessing the hypothesis of essential tremor as a prodromal feature of Parkinson's disease". Parkinsonism Relat Disord. 2025 Mar; 132:107280.
    View in: PubMed
    Score: 0.570
  2. Does Delaying Levodopa Prevent Motor Complications in Parkinson's Disease? A Meta-Analysis. Mov Disord Clin Pract. 2024 Oct; 11(10):1195-1202.
    View in: PubMed
    Score: 0.556
  3. Tapping the Brakes on New Parkinson Disease Biological Staging. JAMA Neurol. 2024 Aug 01; 81(8):789-790.
    View in: PubMed
    Score: 0.553
  4. Botulinum toxin treatment in parkinsonism. J Neurol Sci. 2024 01 15; 456:122810.
    View in: PubMed
    Score: 0.527
  5. Linking the cerebellum to Parkinson disease: an update. Nat Rev Neurol. 2023 11; 19(11):645-654.
    View in: PubMed
    Score: 0.521
  6. Spinal cord stimulation for gait disturbances in Parkinson's disease. Expert Rev Neurother. 2023 Jul-Dec; 23(7):651-659.
    View in: PubMed
    Score: 0.512
  7. How should future clinical trials be designed in the search for disease-modifying therapies for Parkinson's disease? Expert Rev Neurother. 2023 02; 23(2):107-122.
    View in: PubMed
    Score: 0.500
  8. Practical pearls to improve the efficacy and tolerability of levodopa in Parkinson's disease. Expert Rev Neurother. 2022 06; 22(6):489-498.
    View in: PubMed
    Score: 0.477
  9. Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies. CNS Drugs. 2022 04; 36(4):327-343.
    View in: PubMed
    Score: 0.467
  10. The etiopathogenetic and pathophysiological spectrum of parkinsonism. J Neurol Sci. 2022 Feb 15; 433:120012.
    View in: PubMed
    Score: 0.454
  11. Phenotypic Features of Isolated Essential Tremor, Essential Tremor Plus, and Essential Tremor-Parkinson's Disease in a Movement Disorders Clinic. Tremor Other Hyperkinet Mov (N Y). 2021 03 29; 11:12.
    View in: PubMed
    Score: 0.438
  12. Parkinson's disease after COVID-19. J Neurol Sci. 2021 03 15; 422:117331.
    View in: PubMed
    Score: 0.433
  13. Parkinson's disease and skin. Parkinsonism Relat Disord. 2021 01; 82:61-76.
    View in: PubMed
    Score: 0.428
  14. Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy". Mov Disord. 2020 11; 35(11):2120-2121.
    View in: PubMed
    Score: 0.426
  15. A validation of a self-administered screening test for Parkinson's disease. J Neurol Sci. 2020 Nov 15; 418:117116.
    View in: PubMed
    Score: 0.421
  16. Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease. Mov Disord. 2020 08; 35(8):1312-1314.
    View in: PubMed
    Score: 0.417
  17. Parkinson's disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020 08; 91(8):795-808.
    View in: PubMed
    Score: 0.416
  18. Parkinson disease and the immune system - associations, mechanisms and therapeutics. Nat Rev Neurol. 2020 06; 16(6):303-318.
    View in: PubMed
    Score: 0.411
  19. Targeting a-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics. Drugs. 2019 Jun; 79(8):797-810.
    View in: PubMed
    Score: 0.386
  20. Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord. 2019 08; 65:39-48.
    View in: PubMed
    Score: 0.386
  21. Hand, foot, and spine deformities in parkinsonian disorders. J Neural Transm (Vienna). 2019 03; 126(3):253-264.
    View in: PubMed
    Score: 0.379
  22. Essential Tremor and Parkinson's Disease: Exploring the Relationship. Tremor Other Hyperkinet Mov (N Y). 2018; 8:589.
    View in: PubMed
    Score: 0.376
  23. Pathogenesis-targeted therapeutic strategies in Parkinson's disease. Mov Disord. 2019 01; 34(1):41-44.
    View in: PubMed
    Score: 0.373
  24. Reader response: The nature of postural tremor in Parkinson disease. Neurology. 2018 10 09; 91(15):723.
    View in: PubMed
    Score: 0.369
  25. Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2018 10 01; 75(10):1206-1214.
    View in: PubMed
    Score: 0.369
  26. Parkinson's disease tremors and serotonin. Brain. 2018 03 01; 141(3):624-626.
    View in: PubMed
    Score: 0.354
  27. Immunologic treatment of Parkinson's disease. Immunotherapy. 2018 02; 10(2):81-84.
    View in: PubMed
    Score: 0.352
  28. The Role of TMEM230 Gene in Parkinson's Disease. J Parkinsons Dis. 2018; 8(4):469-477.
    View in: PubMed
    Score: 0.350
  29. The genetics of Parkinson disease. Ageing Res Rev. 2018 Mar; 42:72-85.
    View in: PubMed
    Score: 0.350
  30. Parkinson disease: Exenatide - a drug for diabetes and Parkinson disease? Nat Rev Neurol. 2017 Nov; 13(11):643-644.
    View in: PubMed
    Score: 0.344
  31. Anosmia and Ageusia in Parkinson's Disease. Int Rev Neurobiol. 2017; 133:541-556.
    View in: PubMed
    Score: 0.338
  32. Diagnosis and Management of Parkinson's Disease. Semin Neurol. 2017 04; 37(2):118-126.
    View in: PubMed
    Score: 0.335
  33. Media hype: Patient and scientific perspectives on misleading medical news. Mov Disord. 2017 Sep; 32(9):1319-1323.
    View in: PubMed
    Score: 0.333
  34. Movement disorders in 2016: Progress in Parkinson disease and other movement disorders. Nat Rev Neurol. 2017 Feb; 13(2):76-78.
    View in: PubMed
    Score: 0.328
  35. Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. Mov Disord. 2017 03; 32(3):433-440.
    View in: PubMed
    Score: 0.322
  36. New and emerging medical therapies in Parkinson's disease. Expert Opin Pharmacother. 2016; 17(7):895-909.
    View in: PubMed
    Score: 0.308
  37. The relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2016 Jan; 22 Suppl 1:S162-5.
    View in: PubMed
    Score: 0.300
  38. Genetic movement disorders in patients of Jewish ancestry. JAMA Neurol. 2014 Dec; 71(12):1567-72.
    View in: PubMed
    Score: 0.283
  39. The future of research in Parkinson disease. JAMA Neurol. 2014 Nov; 71(11):1351-2.
    View in: PubMed
    Score: 0.281
  40. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson's disease. Parkinsonism Relat Disord. 2014 Dec; 20(12):1345-51.
    View in: PubMed
    Score: 0.279
  41. Genetic convergence of Parkinson's disease and lysosomal storage disorders. Mol Neurobiol. 2015; 51(3):1554-68.
    View in: PubMed
    Score: 0.277
  42. Parkinson disease subtypes. JAMA Neurol. 2014 Apr; 71(4):499-504.
    View in: PubMed
    Score: 0.270
  43. Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial. Parkinsonism Relat Disord. 2014 Jun; 20(6):640-3.
    View in: PubMed
    Score: 0.269
  44. Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics. 2014 Jan; 11(1):92-110.
    View in: PubMed
    Score: 0.265
  45. The VPS35 gene and Parkinson's disease. Mov Disord. 2013 May; 28(5):569-75.
    View in: PubMed
    Score: 0.252
  46. Therapies in Parkinson's disease. Curr Opin Neurol. 2012 Aug; 25(4):433-47.
    View in: PubMed
    Score: 0.241
  47. Current concepts in Parkinson's disease and other movement disorders. Curr Opin Neurol. 2012 Aug; 25(4):429-32.
    View in: PubMed
    Score: 0.241
  48. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat Disord. 2012 Jun; 18(5):488-93.
    View in: PubMed
    Score: 0.233
  49. Pain in Parkinson's disease. Mov Disord. 2012 Apr; 27(4):485-91.
    View in: PubMed
    Score: 0.227
  50. The association between Parkinson's disease and melanoma. Int J Cancer. 2011 May 15; 128(10):2251-60.
    View in: PubMed
    Score: 0.219
  51. Revisiting the relationship between essential tremor and Parkinson's disease. Mov Disord. 2011 Feb 15; 26(3):391-8.
    View in: PubMed
    Score: 0.217
  52. Preclinical biomarkers of Parkinson disease. Arch Neurol. 2011 Jan; 68(1):22-30.
    View in: PubMed
    Score: 0.216
  53. Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. Mov Disord. 2010 May 15; 25(7):961-2; author reply 962-3.
    View in: PubMed
    Score: 0.206
  54. Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of Parkinsonian deformities. Mov Disord. 2010 Apr 15; 25(5):527-8.
    View in: PubMed
    Score: 0.205
  55. Examination of the MASH1 gene in patients with Parkinson's disease. Biochem Biophys Res Commun. 2010 Feb 19; 392(4):548-50.
    View in: PubMed
    Score: 0.202
  56. Examination of the MSX1 gene in patients with Parkinson's disease. Acta Neurol Scand. 2009 Dec; 120(6):442-4.
    View in: PubMed
    Score: 0.200
  57. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord. 2009 Dec; 15 Suppl 3:S224-32.
    View in: PubMed
    Score: 0.200
  58. Genetic analysis of the NEUROG2 gene in patients with Parkinson's disease. Neurosci Lett. 2010 Jan 14; 468(3):195-7.
    View in: PubMed
    Score: 0.199
  59. Relationship between neuropsychological outcome and DBS surgical trajectory and electrode location. J Neurol Sci. 2009 Dec 15; 287(1-2):159-71.
    View in: PubMed
    Score: 0.197
  60. Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2010 Mar; 81(3):315-9.
    View in: PubMed
    Score: 0.197
  61. Transcription factor PITX3 gene in Parkinson's disease. Neurobiol Aging. 2011 Apr; 32(4):750-3.
    View in: PubMed
    Score: 0.192
  62. Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009 Sep 15; 284(1-2):177-8.
    View in: PubMed
    Score: 0.191
  63. Disease-oriented approach to botulinum toxin use. Toxicon. 2009 Oct; 54(5):614-23.
    View in: PubMed
    Score: 0.187
  64. Etiopathogenesis of Parkinson disease: a new beginning? Neuroscientist. 2009 Feb; 15(1):28-35.
    View in: PubMed
    Score: 0.186
  65. Decreased NURR1 gene expression in patients with Parkinson's disease. J Neurol Sci. 2008 Oct 15; 273(1-2):29-33.
    View in: PubMed
    Score: 0.182
  66. Shoulder pain: a presenting symptom of Parkinson disease. J Clin Rheumatol. 2008 Aug; 14(4):253-4.
    View in: PubMed
    Score: 0.182
  67. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008 Apr; 79(4):368-76.
    View in: PubMed
    Score: 0.178
  68. Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist. 2008 Mar; 14(2):89-99.
    View in: PubMed
    Score: 0.177
  69. Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? Ann Neurol. 2008 Mar; 63(3):267-9.
    View in: PubMed
    Score: 0.177
  70. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease. Brain. 2008 Aug; 131(Pt 8):1969-78.
    View in: PubMed
    Score: 0.175
  71. Mutation analysis of the parkin and PINK1 genes in American Caucasian early-onset Parkinson disease families. Neurosci Lett. 2008 Jan 03; 430(1):18-22.
    View in: PubMed
    Score: 0.175
  72. Parkinson's disease and movement disorders: moving forward. Lancet Neurol. 2008 Jan; 7(1):9-11.
    View in: PubMed
    Score: 0.175
  73. Cognitive declines following bilateral subthalamic nucleus deep brain stimulation for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2008 Jul; 79(7):789-95.
    View in: PubMed
    Score: 0.173
  74. Hemiparkinsonism-hemiatrophy syndrome. Neurology. 2007 Oct 16; 69(16):1585-94.
    View in: PubMed
    Score: 0.173
  75. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007 Sep-Oct; 30(5):256-65.
    View in: PubMed
    Score: 0.171
  76. Are Parkinson disease patients protected from some but not all cancers? Neurology. 2007 Oct 09; 69(15):1542-50.
    View in: PubMed
    Score: 0.171
  77. Hereditary chin tremor in Parkinson's disease. Clin Neurol Neurosurg. 2007 Nov; 109(9):784-5.
    View in: PubMed
    Score: 0.169
  78. The effects of subthalamic nucleus deep brain stimulation on parkinsonian tremor. J Neurol Sci. 2007 Sep 15; 260(1-2):199-203.
    View in: PubMed
    Score: 0.168
  79. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. Expert Rev Neurother. 2007 Jun; 7(6):637-47.
    View in: PubMed
    Score: 0.168
  80. Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome. Expert Opin Pharmacother. 2007 Jun; 8(9):1329-35.
    View in: PubMed
    Score: 0.168
  81. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007 May; 64(5):676-82.
    View in: PubMed
    Score: 0.167
  82. Genetic analysis of LRRK2 P755L variant in Caucasian patients with Parkinson's disease. Neurosci Lett. 2007 May 29; 419(2):104-7.
    View in: PubMed
    Score: 0.167
  83. A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations. Arch Neurol. 2007 Mar; 64(3):421-4.
    View in: PubMed
    Score: 0.165
  84. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs. 2007; 21(8):677-92.
    View in: PubMed
    Score: 0.163
  85. Comparing knowledge and attitudes towards genetic testing in Parkinson's disease in an American and Asian population. J Neurol Sci. 2007 Jan 31; 252(2):113-20.
    View in: PubMed
    Score: 0.163
  86. Genetic analysis of LRRK2 mutations in patients with Parkinson disease. J Neurol Sci. 2006 Dec 21; 251(1-2):102-6.
    View in: PubMed
    Score: 0.162
  87. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord. 2006 Nov; 21(11):1856-63.
    View in: PubMed
    Score: 0.162
  88. Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol. 2006 Sep; 63(9):1232-7.
    View in: PubMed
    Score: 0.160
  89. Exploring the relationship between essential tremor and Parkinson's disease. Parkinsonism Relat Disord. 2007 Mar; 13(2):67-76.
    View in: PubMed
    Score: 0.159
  90. Subthalamic deep brain stimulation in patients with a previous pallidotomy. Mov Disord. 2006 Aug; 21(8):1252-4.
    View in: PubMed
    Score: 0.159
  91. Treatment of advanced Parkinson's disease. Expert Rev Neurother. 2006 Aug; 6(8):1181-97.
    View in: PubMed
    Score: 0.159
  92. An update on the treatment of Parkinson's disease. Mt Sinai J Med. 2006 Jul; 73(4):682-9.
    View in: PubMed
    Score: 0.158
  93. Gene dosage analysis of alpha-synuclein (SNCA) in patients with Parkinson's disease. Mov Disord. 2006 May; 21(5):728-9.
    View in: PubMed
    Score: 0.156
  94. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg. 2006 Apr; 104(4):506-12.
    View in: PubMed
    Score: 0.155
  95. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch Neurol. 2006 Feb; 63(2):273-7.
    View in: PubMed
    Score: 0.153
  96. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry. 2005 Dec; 76(12):1636-9.
    View in: PubMed
    Score: 0.152
  97. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol. 2005 Sep-Oct; 77(1-2):128-38.
    View in: PubMed
    Score: 0.150
  98. Dystonia and other deformities in Parkinson's disease. J Neurol Sci. 2005 Dec 15; 239(1):1-3.
    View in: PubMed
    Score: 0.150
  99. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry. 2005 Sep; 76(9):1188-93.
    View in: PubMed
    Score: 0.149
  100. Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol. 2005 Jul; 4(7):423-31.
    View in: PubMed
    Score: 0.147
  101. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology. 2005 Jun 28; 64(12):2021-8.
    View in: PubMed
    Score: 0.147
  102. G309D and W437OPA PINK1 mutations in Caucasian Parkinson's disease patients. Acta Neurol Scand. 2005 Jun; 111(6):351-2.
    View in: PubMed
    Score: 0.146
  103. Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation. Ann Neurol. 2005 Jun; 57(6):933-4.
    View in: PubMed
    Score: 0.146
  104. Progression of Parkinson disease: are we making progress in charting the course? Arch Neurol. 2005 Mar; 62(3):351-2.
    View in: PubMed
    Score: 0.144
  105. Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations. Mov Disord. 2005; 20 Suppl 11:S11-6.
    View in: PubMed
    Score: 0.142
  106. Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord. 2005; 20 Suppl 11:S3-10.
    View in: PubMed
    Score: 0.142
  107. Essential tremor course and disability: a clinicopathologic study of 20 cases. Neurology. 2004 Oct 26; 63(8):1541-2; author reply 1541-2.
    View in: PubMed
    Score: 0.140
  108. Drug-induced parkinsonism: diagnosis and treatment. Expert Opin Drug Saf. 2024 Dec; 23(12):1503-1513.
    View in: PubMed
    Score: 0.140
  109. Premutation alleles associated with Parkinson disease and essential tremor. JAMA. 2004 Oct 13; 292(14):1685-6.
    View in: PubMed
    Score: 0.140
  110. Glabellar and palmomental reflexes in Parkinsonian disorders. Neurology. 2004 Sep 28; 63(6):1096-8.
    View in: PubMed
    Score: 0.140
  111. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology. 2004 Jan 27; 62(2):343; author reply 343-4.
    View in: PubMed
    Score: 0.133
  112. Dopamine agonists in Parkinson's disease. Expert Opin Investig Drugs. 2003 Nov; 12(11):1803-20.
    View in: PubMed
    Score: 0.131
  113. Establishing an online resource to facilitate global collaboration and inclusion of underrepresented populations: Experience from the MJFF Global Genetic Parkinson's Disease Project. PLoS One. 2023; 18(10):e0292180.
    View in: PubMed
    Score: 0.130
  114. Retinal Thickness in Essential Tremor and Early Parkinson Disease: Exploring Diagnostic Insights. J Neuroophthalmol. 2024 Mar 01; 44(1):35-40.
    View in: PubMed
    Score: 0.129
  115. Neuroprotection in Parkinson disease. Arch Intern Med. 2003 Jul 28; 163(14):1650-4.
    View in: PubMed
    Score: 0.129
  116. Isolated Cervical Dystonia: Diagnosis and Classification. Mov Disord. 2023 08; 38(8):1367-1378.
    View in: PubMed
    Score: 0.126
  117. Embracing Monogenic Parkinson's Disease: The MJFF Global Genetic PD Cohort. Mov Disord. 2023 02; 38(2):286-303.
    View in: PubMed
    Score: 0.124
  118. Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease. Clin Neuropharmacol. 2003 Jan-Feb; 26(1):18-23.
    View in: PubMed
    Score: 0.124
  119. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002 Sep; 17(5):1031-5.
    View in: PubMed
    Score: 0.121
  120. Association of clinical outcomes and connectivity in awake versus asleep deep brain stimulation for Parkinson disease. J Neurosurg. 2023 04 01; 138(4):1016-1027.
    View in: PubMed
    Score: 0.120
  121. Treatment options for Parkinson's disease. Curr Opin Neurol. 2002 Aug; 15(4):467-76.
    View in: PubMed
    Score: 0.120
  122. H-reflex recovery curves differentiate essential tremor, Parkinson's disease, and the combination of essential tremor and Parkinson's disease. J Clin Neurophysiol. 2002 Jun; 19(3):245-51.
    View in: PubMed
    Score: 0.119
  123. Exploring the relationship between Parkinson disease and restless legs syndrome. Arch Neurol. 2002 Mar; 59(3):421-4.
    View in: PubMed
    Score: 0.117
  124. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002 Mar; 8(4):271-6.
    View in: PubMed
    Score: 0.117
  125. Levodopa strengths and weaknesses. Neurology. 2002 Feb 26; 58(4 Suppl 1):S19-32.
    View in: PubMed
    Score: 0.117
  126. Emerging views of dopamine in modulating sleep/wake state from an unlikely source: PD. Neurology. 2002 Feb 12; 58(3):341-6.
    View in: PubMed
    Score: 0.116
  127. Methods of H-reflex evaluation in the early stages of Parkinson's disease. J Clin Neurophysiol. 2002 Jan; 19(1):67-72.
    View in: PubMed
    Score: 0.116
  128. Surgery for Parkinson disease and other movement disorders: benefits and limitations of ablation, stimulation, restoration, and radiation. Arch Neurol. 2001 Dec; 58(12):1970-2.
    View in: PubMed
    Score: 0.115
  129. Parkinson's disease. A half century of progress. Neurology. 2001 Nov; 57(10 Suppl 3):S1-3.
    View in: PubMed
    Score: 0.114
  130. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. 2001 Oct 23; 57(8):1392-6.
    View in: PubMed
    Score: 0.114
  131. Functional decline in Parkinson disease. Arch Neurol. 2001 Oct; 58(10):1611-5.
    View in: PubMed
    Score: 0.114
  132. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol. 2001 Sep-Oct; 24(5):247-53.
    View in: PubMed
    Score: 0.113
  133. Parkinson's disease therapy: treatment of early and late disease. Chin Med J (Engl). 2001 Mar; 114(3):227-34.
    View in: PubMed
    Score: 0.109
  134. Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity. Parkinsonism Relat Disord. 2021 03; 84:105-111.
    View in: PubMed
    Score: 0.109
  135. Re-emergence of childhood stuttering in Parkinson's disease: a hypothesis. Mov Disord. 2001 Jan; 16(1):114-8.
    View in: PubMed
    Score: 0.108
  136. Switching from pergolide to pramipexole in patients with Parkinson's disease. J Neural Transm (Vienna). 2001; 108(1):63-70.
    View in: PubMed
    Score: 0.108
  137. Effects of pallidotomy on gait and balance. Adv Neurol. 2001; 87:271-81.
    View in: PubMed
    Score: 0.108
  138. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging. 2001; 18(6):389-96.
    View in: PubMed
    Score: 0.108
  139. Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol. 2000 Sep-Oct; 23(5):252-61.
    View in: PubMed
    Score: 0.105
  140. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol. 2000 Mar; 57(3):369-72.
    View in: PubMed
    Score: 0.102
  141. Complications and limitations of drug therapy for Parkinson's disease. Neurology. 2000; 55(12 Suppl 6):S2-6.
    View in: PubMed
    Score: 0.101
  142. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain. 2020 01 01; 143(1):234-248.
    View in: PubMed
    Score: 0.101
  143. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease. J Parkinsons Dis. 2020; 10(2):543-558.
    View in: PubMed
    Score: 0.101
  144. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019 12; 18(12):1091-1102.
    View in: PubMed
    Score: 0.100
  145. Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1999 Nov; 67(5):646-50.
    View in: PubMed
    Score: 0.099
  146. Levodopa-induced dyskinesias treated by pallidotomy. J Neurol Sci. 1999 Aug 01; 167(1):62-7.
    View in: PubMed
    Score: 0.098
  147. New and emerging therapies for Parkinson disease. Arch Neurol. 1999 Jul; 56(7):785-90.
    View in: PubMed
    Score: 0.097
  148. A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease. Mov Disord. 1999 Jul; 14(4):664-8.
    View in: PubMed
    Score: 0.097
  149. Exercise performance in those having Parkinson's disease and healthy normals. Med Sci Sports Exerc. 1999 Jun; 31(6):761-6.
    View in: PubMed
    Score: 0.097
  150. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and a-synuclein mechanisms. Mov Disord. 2019 06; 34(6):866-875.
    View in: PubMed
    Score: 0.096
  151. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999 Jan; 14(1):57-62.
    View in: PubMed
    Score: 0.094
  152. Clinical correlates of vascular parkinsonism. Arch Neurol. 1999 Jan; 56(1):98-102.
    View in: PubMed
    Score: 0.094
  153. Efficacy and tolerability of a novel sublingual apomorphine preparation in patients with fluctuating Parkinson's disease. Clin Neuropharmacol. 1999 Jan-Feb; 22(1):1-4.
    View in: PubMed
    Score: 0.094
  154. Attitudes toward neurosurgical procedures for Parkinson's disease and obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci. 1999; 11(2):259-67.
    View in: PubMed
    Score: 0.094
  155. Local field potentials of subthalamic nucleus contain electrophysiological footprints of motor subtypes of Parkinson's disease. Proc Natl Acad Sci U S A. 2018 09 04; 115(36):E8567-E8576.
    View in: PubMed
    Score: 0.092
  156. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain. 2017 12 01; 140(12):3191-3203.
    View in: PubMed
    Score: 0.087
  157. Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial. JAMA Neurol. 2017 Feb 01; 74(2):216-224.
    View in: PubMed
    Score: 0.082
  158. Improvement of parkinsonian signs after vascular lesions of the basal ganglia circuitry. Mov Disord. 1997 Jan; 12(1):124-6.
    View in: PubMed
    Score: 0.082
  159. [Medial posteroventral pallidotomy for the treatment of Parkinson's disease]. Zentralbl Neurochir. 1997; 58(4):153-62.
    View in: PubMed
    Score: 0.082
  160. Surgical treatment of Parkinson's disease. Am Fam Physician. 1996 Oct; 54(5):1621-9.
    View in: PubMed
    Score: 0.080
  161. Propofol-induced dyskinesias in Parkinson's disease. Anesth Analg. 1996 Aug; 83(2):420-22.
    View in: PubMed
    Score: 0.079
  162. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet. 2016 07; 48(7):733-9.
    View in: PubMed
    Score: 0.079
  163. Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia. Drugs. 2016 May; 76(7):779-87.
    View in: PubMed
    Score: 0.078
  164. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia. Drugs. 2016 May; 76(7):759-77.
    View in: PubMed
    Score: 0.078
  165. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995 Oct; 37(4):680-6; discussion 686-7.
    View in: PubMed
    Score: 0.075
  166. Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits. Mov Disord. 2015 Dec; 30(14):1885-92.
    View in: PubMed
    Score: 0.074
  167. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
    View in: PubMed
    Score: 0.073
  168. A Pilot Study of a Cognitive-Behavioral Treatment for Anxiety and Depression in Patients With Parkinson Disease. J Geriatr Psychiatry Neurol. 2015 Sep; 28(3):210-7.
    View in: PubMed
    Score: 0.073
  169. Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects. Neurology. 1995 Apr; 45(4):645-8.
    View in: PubMed
    Score: 0.072
  170. Peripherally induced tremor and parkinsonism. Arch Neurol. 1995 Mar; 52(3):263-70.
    View in: PubMed
    Score: 0.072
  171. Epigenetic mechanisms in Parkinson's disease. J Neurol Sci. 2015 Feb 15; 349(1-2):3-9.
    View in: PubMed
    Score: 0.071
  172. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord. 2014 Aug; 29(9):1171-80.
    View in: PubMed
    Score: 0.068
  173. What is it? Case 1, 1993: parkinsonism, dysautonomia, and ophthalmoparesis. Mov Disord. 1993 Oct; 8(4):525-32.
    View in: PubMed
    Score: 0.065
  174. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease. Parkinsonism Relat Disord. 2014 Feb; 20(2):142-8.
    View in: PubMed
    Score: 0.065
  175. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: comparison with the unified Parkinson's disease rating scale. Mov Disord. 2013 May; 28(5):668-70.
    View in: PubMed
    Score: 0.062
  176. The role of alpha-synuclein in melanin synthesis in melanoma and dopaminergic neuronal cells. PLoS One. 2012; 7(9):e45183.
    View in: PubMed
    Score: 0.061
  177. Emerging therapies for Parkinson's disease. Curr Opin Neurol. 2012 Aug; 25(4):448-59.
    View in: PubMed
    Score: 0.060
  178. Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed? J Neural Transm (Vienna). 2013 Jan; 120(1):197-210.
    View in: PubMed
    Score: 0.060
  179. Alternating verbal fluency performance following bilateral subthalamic nucleus deep brain stimulation for Parkinson's disease. Eur J Neurol. 2012 Dec; 19(12):1525-31.
    View in: PubMed
    Score: 0.059
  180. Low body weight in Parkinson's disease. South Med J. 1992 Apr; 85(4):351-4.
    View in: PubMed
    Score: 0.059
  181. Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol. 2012 Feb; 11(2):140-9.
    View in: PubMed
    Score: 0.058
  182. Head injury, a-synuclein Rep1, and Parkinson's disease. Ann Neurol. 2012 Jan; 71(1):40-8.
    View in: PubMed
    Score: 0.058
  183. Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord. 2012 Feb; 27(2):284-8.
    View in: PubMed
    Score: 0.058
  184. The prevalence of symptomatic orthostatic hypotension in patients with Parkinson's disease and atypical parkinsonism. Parkinsonism Relat Disord. 2011 Sep; 17(8):625-8.
    View in: PubMed
    Score: 0.056
  185. Changes in cognitive-emotional and physiological symptoms of depression following STN-DBS for the treatment of Parkinson's disease. Eur J Neurol. 2012 Jan; 19(1):121-7.
    View in: PubMed
    Score: 0.056
  186. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol. 2011 May; 10(5):415-23.
    View in: PubMed
    Score: 0.055
  187. Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease. Mov Disord. 2011 Aug 01; 26(9):1729-32.
    View in: PubMed
    Score: 0.055
  188. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol. 2011 Apr; 178(4):1509-16.
    View in: PubMed
    Score: 0.055
  189. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol. 2011 Mar; 69(3):570-80.
    View in: PubMed
    Score: 0.055
  190. Cognitive outcome and reliable change indices two years following bilateral subthalamic nucleus deep brain stimulation. Parkinsonism Relat Disord. 2011 Jun; 17(5):321-7.
    View in: PubMed
    Score: 0.054
  191. CSF A?(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord. 2010 Nov 15; 25(15):2682-5.
    View in: PubMed
    Score: 0.053
  192. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
    View in: PubMed
    Score: 0.053
  193. LINGO1 rs9652490 variant in Parkinson disease patients. Neurosci Lett. 2011 Jan 07; 487(2):174-6.
    View in: PubMed
    Score: 0.053
  194. Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct; 40(10):1529-34.
    View in: PubMed
    Score: 0.053
  195. Respiratory problems in neurologic movement disorders. Parkinsonism Relat Disord. 2010 Dec; 16(10):628-38.
    View in: PubMed
    Score: 0.052
  196. Nonlinear temporal organization of neuronal discharge in the basal ganglia of Parkinson's disease patients. Exp Neurol. 2010 Aug; 224(2):542-4.
    View in: PubMed
    Score: 0.052
  197. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol. 2010 Jul; 68(1):18-27.
    View in: PubMed
    Score: 0.052
  198. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010 Aug 09; 480(1):78-82.
    View in: PubMed
    Score: 0.052
  199. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010 May; 31(5):561-8.
    View in: PubMed
    Score: 0.051
  200. LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics. 2010 Oct; 11(4):401-8.
    View in: PubMed
    Score: 0.051
  201. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010 Mar; 133(Pt 3):713-26.
    View in: PubMed
    Score: 0.051
  202. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration. Neurobiol Dis. 2010 Feb; 37(2):307-13.
    View in: PubMed
    Score: 0.049
  203. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med. 2009 Sep 24; 361(13):1268-78.
    View in: PubMed
    Score: 0.049
  204. Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease. Neurology. 1989 Sep; 39(9):1227-34.
    View in: PubMed
    Score: 0.049
  205. Occupation and risk of parkinsonism: a multicenter case-control study. Arch Neurol. 2009 Sep; 66(9):1106-13.
    View in: PubMed
    Score: 0.049
  206. Movement disorders. Preface. Neurol Clin. 2009 Aug; 27(3):ix-x.
    View in: PubMed
    Score: 0.049
  207. The course of depressive symptoms in early Parkinson's disease. Mov Disord. 2009 Jul 15; 24(9):1306-11.
    View in: PubMed
    Score: 0.049
  208. Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics. 2009 Oct; 10(4):347-53.
    View in: PubMed
    Score: 0.048
  209. GIGYF2 Asn56Ser and Asn457Thr mutations in Parkinson disease patients. Neurosci Lett. 2009 May 01; 454(3):209-11.
    View in: PubMed
    Score: 0.048
  210. Parkinsonism-plus syndromes. Mov Disord. 1989; 4 Suppl 1:S95-119.
    View in: PubMed
    Score: 0.047
  211. Comparison of Sinemet CR4 and standard Sinemet: double blind and long-term open trial in parkinsonian patients with fluctuations. Mov Disord. 1989; 4(4):303-9.
    View in: PubMed
    Score: 0.047
  212. Lower body parkinsonism: evidence for vascular etiology. Mov Disord. 1989; 4(3):249-60.
    View in: PubMed
    Score: 0.047
  213. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008 Nov 15; 23(15):2194-201.
    View in: PubMed
    Score: 0.047
  214. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15; 23(15):2129-70.
    View in: PubMed
    Score: 0.047
  215. Parkinson's disease: recent advances in therapy. South Med J. 1988 Aug; 81(8):1021-7.
    View in: PubMed
    Score: 0.046
  216. Five-year follow-up of unilateral posteroventral pallidotomy in Parkinson's disease. Surg Neurol. 2009 May; 71(5):551-8.
    View in: PubMed
    Score: 0.045
  217. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol. 2008 Apr; 129(4):526-9.
    View in: PubMed
    Score: 0.045
  218. Bilateral pedunculopontine nuclei strokes presenting as freezing of gait. Mov Disord. 2008 Mar 15; 23(4):616-9.
    View in: PubMed
    Score: 0.044
  219. Case 2, 1988. Congenital mental retardation and juvenile parkinsonism. Mov Disord. 1988; 3(4):352-61.
    View in: PubMed
    Score: 0.044
  220. Coexistent tardive dyskinesia and parkinsonism. Clin Neuropharmacol. 1987 Dec; 10(6):511-21.
    View in: PubMed
    Score: 0.044
  221. Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis. Acta Neurochir (Wien). 2007; 149(9):857-66; discussion 866.
    View in: PubMed
    Score: 0.042
  222. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007 Jul 24; 69(4):342-7.
    View in: PubMed
    Score: 0.042
  223. A founding LRRK2 haplotype shared by Tunisian, US, European and Middle Eastern families with Parkinson's disease. Parkinsonism Relat Disord. 2008; 14(1):77-80.
    View in: PubMed
    Score: 0.042
  224. Genetics of essential tremor. Brain. 2007 Jun; 130(Pt 6):1456-64.
    View in: PubMed
    Score: 0.041
  225. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007 Jan 23; 68(4):272-6.
    View in: PubMed
    Score: 0.041
  226. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. 2007 Jan; 22(1):41-7.
    View in: PubMed
    Score: 0.041
  227. Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. Mov Disord. 2007 Jan; 22(1):55-61.
    View in: PubMed
    Score: 0.041
  228. The LRRK2 I2012T, G2019S and I2020T mutations are not common in patients with essential tremor. Neurosci Lett. 2006 Oct 23; 407(2):97-100.
    View in: PubMed
    Score: 0.040
  229. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis. 2006 Aug; 9(3):293-348.
    View in: PubMed
    Score: 0.040
  230. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.038
  231. Parkinsonism and acquired hydrocephalus. Mov Disord. 1986; 1(1):59-64.
    View in: PubMed
    Score: 0.038
  232. Camptocormia: pathogenesis, classification, and response to therapy. Neurology. 2005 Aug 09; 65(3):355-9.
    View in: PubMed
    Score: 0.037
  233. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol. 2005 Aug; 62(8):1290-5.
    View in: PubMed
    Score: 0.037
  234. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004 Jul; 61(7):1044-53.
    View in: PubMed
    Score: 0.034
  235. Apolipoprotein E controls the risk and age at onset of Parkinson disease. Neurology. 2004 Jun 08; 62(11):2005-9.
    View in: PubMed
    Score: 0.034
  236. Effects of visual and auditory cues on gait in individuals with Parkinson's disease. J Neurol Sci. 2004 Apr 15; 219(1-2):63-9.
    View in: PubMed
    Score: 0.034
  237. Dopaminergic properties and experimental anti-parkinsonian effects of IPX750 in rodent models of Parkinson disease. Clin Neuropharmacol. 2004 Mar-Apr; 27(2):63-73.
    View in: PubMed
    Score: 0.034
  238. Clinical gait and balance scale (GABS): validation and utilization. J Neurol Sci. 2004 Jan 15; 217(1):89-99.
    View in: PubMed
    Score: 0.033
  239. Hearing impairment in essential tremor. Neurology. 2003 Oct 28; 61(8):1093-7.
    View in: PubMed
    Score: 0.033
  240. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003 Dec 15; 12(24):3259-67.
    View in: PubMed
    Score: 0.033
  241. Association study of Parkin gene polymorphisms with idiopathic Parkinson disease. Arch Neurol. 2003 Jul; 60(7):975-80.
    View in: PubMed
    Score: 0.032
  242. Basal ganglia neuronal discharge in primary and secondary dystonia in patients undergoing pallidotomy. Neurosurgery. 2003 Jun; 52(6):1358-70; discussion 1370-3.
    View in: PubMed
    Score: 0.032
  243. Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease. Neurology. 2003 Apr 08; 60(7):1189-91.
    View in: PubMed
    Score: 0.032
  244. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet. 2003 Apr; 72(4):804-11.
    View in: PubMed
    Score: 0.031
  245. Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging. 2003; 20(10):711-21.
    View in: PubMed
    Score: 0.031
  246. Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet. 2003 Jan; 33(1):85-9.
    View in: PubMed
    Score: 0.031
  247. Essential tremor: a heterogenous disorder. Mov Disord. 2002 Jul; 17(4):638-44.
    View in: PubMed
    Score: 0.030
  248. Association of homozygous 7048G7049 variant in the intron six of Nurr1 gene with Parkinson's disease. Neurology. 2002 Mar 26; 58(6):881-4.
    View in: PubMed
    Score: 0.029
  249. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002 Apr; 70(4):985-93.
    View in: PubMed
    Score: 0.029
  250. Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA. 2001 Nov 14; 286(18):2239-44.
    View in: PubMed
    Score: 0.029
  251. Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA. 2001 Nov 14; 286(18):2245-50.
    View in: PubMed
    Score: 0.029
  252. Thalamic deep brain stimulation: effects on the nontarget limbs. Mov Disord. 2001 Nov; 16(6):1137-42.
    View in: PubMed
    Score: 0.029
  253. Alcohol dehydrogenase polymorphism and Parkinson's disease. Neurosci Lett. 2001 Jun 01; 305(1):70-2.
    View in: PubMed
    Score: 0.028
  254. Thalamic deep brain stimulation: comparison between unilateral and bilateral placement. Arch Neurol. 2001 Feb; 58(2):218-22.
    View in: PubMed
    Score: 0.027
  255. Long-term efficacy of posteroventral pallidotomy in the treatment of Parkinson's disease. Neurology. 2000 Oct 24; 55(8):1218-22.
    View in: PubMed
    Score: 0.027
  256. Postural control in Parkinson's disease after unilateral posteroventral pallidotomy. Brain. 2000 Oct; 123 ( Pt 10):2141-9.
    View in: PubMed
    Score: 0.026
  257. Computerized posturography analysis of progressive supranuclear palsy: a case-control comparison with Parkinson's disease and healthy controls. Arch Neurol. 2000 Oct; 57(10):1464-9.
    View in: PubMed
    Score: 0.026
  258. Neuropsychological outcome after unilateral pallidotomy for the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2000 Sep; 69(3):326-36.
    View in: PubMed
    Score: 0.026
  259. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology. 2000 Aug 22; 55(4):533-8.
    View in: PubMed
    Score: 0.026
  260. Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology. 2000 Mar 14; 54(5):1195-8.
    View in: PubMed
    Score: 0.025
  261. Essential tremor: clinical characteristics. Neurology. 2000; 54(11 Suppl 4):S21-5.
    View in: PubMed
    Score: 0.025
  262. Antioxidant property of pramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm (Vienna). 2000; 107(10):1165-73.
    View in: PubMed
    Score: 0.025
  263. The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics. 1999 Sep; 2(3):191-2.
    View in: PubMed
    Score: 0.025
  264. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch Neurol. 1999 Feb; 56(2):194-200.
    View in: PubMed
    Score: 0.024
  265. The G209A mutation in the alpha-synuclein gene is not detected in familial cases of Parkinson disease in non-Greek and/or Italian populations. Arch Neurol. 1998 Dec; 55(12):1521-3.
    View in: PubMed
    Score: 0.023
  266. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology. 1998 Oct; 51(4):1063-9.
    View in: PubMed
    Score: 0.023
  267. Posteroventral medial pallidotomy for treatment of Parkinson's disease: preoperative magnetic resonance imaging features and clinical outcome. J Neurosurg. 1998 Aug; 89(2):194-9.
    View in: PubMed
    Score: 0.023
  268. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. 1998 Jul; 55(7):969-78.
    View in: PubMed
    Score: 0.023
  269. Consensus for the measurement of the camptocormia angle in the standing patient. Parkinsonism Relat Disord. 2018 07; 52:1-5.
    View in: PubMed
    Score: 0.023
  270. Assessment of motor function after stereotactic pallidotomy. Neurology. 1998 Jan; 50(1):266-70.
    View in: PubMed
    Score: 0.022
  271. Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson's disease: postoperative magnetic resonance imaging analysis. J Neurosurg. 1997 Sep; 87(3):358-67.
    View in: PubMed
    Score: 0.021
  272. Posteroventral medial pallidotomy in levodopa-unresponsive parkinsonism. Arch Neurol. 1997 Aug; 54(8):1026-9.
    View in: PubMed
    Score: 0.021
  273. Familial essential tremor in 4 kindreds. Prospects for genetic mapping. Arch Neurol. 1997 Mar; 54(3):289-94.
    View in: PubMed
    Score: 0.021
  274. Thalamic surgery for movement disorders. Adv Neurol. 1997; 74:221-33.
    View in: PubMed
    Score: 0.020
  275. Clozapine for acute and maintenance treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 1995; 7(4):471-5.
    View in: PubMed
    Score: 0.018
  276. Post-traumatic movement disorders: central and peripheral mechanisms. Neurology. 1994 Nov; 44(11):2006-14.
    View in: PubMed
    Score: 0.018
  277. Sensory aspects of movement disorders. Lancet Neurol. 2014 Jan; 13(1):100-12.
    View in: PubMed
    Score: 0.017
  278. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis. 2008 Oct; 32(1):16-25.
    View in: PubMed
    Score: 0.011
  279. Depressed mood and memory impairment before and after unilateral posteroventral pallidotomy in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2008; 20(3):357-63.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.